By Government of Saskatchewan

Province Enhancing Cancer Treatment Safety Through Genotyping

Aug 15, 2024 | 11:33 AM

The Government of Saskatchewan, Saskatchewan Health Authority (SHA), and Saskatchewan Cancer Agency (SCA) are launching a genome testing program to improve the safety of Saskatchewan cancer patients receiving chemotherapy treatment.

Patients eligible for treatment with fluoropyrimidine-based drugs who may face severe or life-threatening side effects can now have in-province DPYD genotyping done before starting their treatment. This test identifies genetic variants in the DPYD gene, which affects the production of the DPD (dihydropyrimidine dehydrogenase) enzyme.

“Screening for these genetic variants can help improve treatment outcomes for Saskatchewan cancer patients,” Health Minister Everett Hindley said. “The introduction of DPYD genome testing shows our commitment to both precision medicine and patient safety. By making this a standard part of oncology practice, health-care providers can better manage treatment plans and potential complications.”

Previously, DPYD testing was done in the U.S. with a two-week turnaround time. Now, the Royal University Hospital Pharmacogenomic Lab in Saskatoon is offering the test locally, with results in 2 to 7 days. The lab expects to test around 1,000 patients annually.

“Conducting rapid testing for DPD enzyme deficiencies right here in Saskatchewan helps our teams provide safer and more effective care as quickly as possible for cancer patients across the province, by appropriately adjusting their care plans before they receive treatment,” SHA Provincial Clinical and Support Services Vice President Bryan Witt said. “This is a positive step in continuing to explore innovative solutions that improve patient-centred outcomes and reaffirms our commitment to advancing personalized medicine.”

National

Ottawa to remove 30% investment cap for Canadian pension funds

3h ago

Budget woes

Golf and curling centre faces grim season without financial boost

6h ago

Raiders AGM

Raiders impact on Prince Albert local economy continues to go up: AGM report

Dec 12, 2024

“Offering screening for DPD enzyme deficiency in Saskatchewan is one way we are ensuring cancer patients have access to the highest standard of care,” Saskatchewan Cancer Agency Medical Services Vice-President Dr. Shazia Mahmood said. “Fluoropyrimidine based chemotherapy drugs are commonly used to treat multiple cancers, and DPD enzyme deficiency can lead to severe life-threatening toxicities in some patients. The Cancer Agency is pleased this testing will be offered to patients who are at risk in our ongoing efforts to ensure patient safety.”

This initiative marks a significant advancement in cancer care, with Saskatchewan becoming the fourth province to implement DPYD testing. It aligns with global best practices and ensures our health care remains at the forefront of cancer treatment innovation.